BRPI0919485A2 - vacinas, antígenos, composições de plasmodium e métodos - Google Patents

vacinas, antígenos, composições de plasmodium e métodos

Info

Publication number
BRPI0919485A2
BRPI0919485A2 BRPI0919485A BRPI0919485A BRPI0919485A2 BR PI0919485 A2 BRPI0919485 A2 BR PI0919485A2 BR PI0919485 A BRPI0919485 A BR PI0919485A BR PI0919485 A BRPI0919485 A BR PI0919485A BR PI0919485 A2 BRPI0919485 A2 BR PI0919485A2
Authority
BR
Brazil
Prior art keywords
plasmodium
vaccines
antigens
compositions
methods
Prior art date
Application number
BRPI0919485A
Other languages
English (en)
Inventor
Christine E Farrance
Konstantin Musiychuk
Vadim Mett
Vidadi Yusibov
Original Assignee
Fraunhofer Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Usa Inc filed Critical Fraunhofer Usa Inc
Publication of BRPI0919485A2 publication Critical patent/BRPI0919485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01073—Licheninase (3.2.1.73)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2448—Licheninase (3.2.1.73)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0919485A 2008-09-28 2009-09-28 vacinas, antígenos, composições de plasmodium e métodos BRPI0919485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10074408P 2008-09-28 2008-09-28
PCT/US2009/058669 WO2010037063A2 (en) 2008-09-28 2009-09-28 Plasmodium vaccines, antigens, compositions and methods

Publications (1)

Publication Number Publication Date
BRPI0919485A2 true BRPI0919485A2 (pt) 2015-12-01

Family

ID=41571118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919485A BRPI0919485A2 (pt) 2008-09-28 2009-09-28 vacinas, antígenos, composições de plasmodium e métodos

Country Status (7)

Country Link
US (1) US20110314575A1 (pt)
EP (1) EP2352751A2 (pt)
CN (1) CN102227444A (pt)
AU (1) AU2009296268A1 (pt)
BR (1) BRPI0919485A2 (pt)
CA (1) CA2738756A1 (pt)
WO (1) WO2010037063A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US8858959B2 (en) 2011-07-15 2014-10-14 The United States Of America, As Represented By The Secretary Of Agriculture Gel vaccine delivery system for treating poultry
CN103965321B (zh) * 2013-01-28 2016-06-22 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
EP2796147A1 (en) 2013-04-24 2014-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel vaccines against apicomplexan pathoges
EP2923709A1 (en) * 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
CN110894218B (zh) * 2019-12-17 2022-04-29 南京农业大学 致病疫霉菌分泌的植物免疫激活蛋白scr50及其应用
US20230390372A1 (en) * 2020-08-28 2023-12-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Compositions and methods for targeting plasmodium male gamete protein to block malaria parasite transmission
WO2025254689A1 (en) * 2024-06-07 2025-12-11 The Trustees Of The University Of Pennsylvania Mutated kras peptide-specific compositions and methods
WO2026047168A1 (en) * 2024-08-30 2026-03-05 Stichting Radboud Universitair Medisch Centrum Polypeptide subdomain malaria vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427641T3 (es) * 2003-05-22 2013-10-31 Ibio, Inc. Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
WO2006124712A2 (en) * 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
CA2642138A1 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Production of foreign nucleic acids and polypeptides in plant systems
WO2008048945A2 (en) * 2006-10-16 2008-04-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Conjugates of plasmodium falciparum surface proteins as malaria vaccines
FR2911608B1 (fr) * 2007-01-23 2009-04-03 Centre Nat Rech Scient Nouvelles compositions vaccinales anti paludique et ses utilisations.
CA2696764A1 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009058355A2 (en) * 2007-10-31 2009-05-07 University Of Central Florida Research Foundation, Inc. Chloroplast-derived human vaccine antigens against malaria

Also Published As

Publication number Publication date
WO2010037063A3 (en) 2010-07-22
AU2009296268A1 (en) 2010-04-01
US20110314575A1 (en) 2011-12-22
CN102227444A (zh) 2011-10-26
CA2738756A1 (en) 2010-04-01
WO2010037063A2 (en) 2010-04-01
EP2352751A2 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
BRPI0909770A2 (pt) Vacina, e, kit
DK2200646T3 (da) RNA-Vacciner
IL248607A (en) Methods and compositions for immunization against virus
BRPI0919575A2 (pt) método, e, composição
HUE031343T2 (hu) Immunitásindukáló ágens
BRPI0917205A2 (pt) vacina polivalente
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0913227A2 (pt) método, e objeto
DK2049559T3 (da) Forbedrede HPV vacciner
BRPI0814594A2 (pt) Composições e métodos adjuvantes de antígeno
BR112012001172A2 (pt) artigo, e, método
BRPI0823277A2 (pt) Composição, e , método
DK2114993T3 (da) Vaccine
BRPI0917370A2 (pt) anticorpos anti-il-13 manipulados, composições, métodos e usos.
PL2356462T3 (pl) Kompozycje anty-CXCR1 oraz sposoby
IL208660A0 (en) Coccididosis vaccines
BRPI0810865A2 (pt) antígenos de tripanossoma, composições vacinais, e métodos relacionados
BRPI0822472A2 (pt) Método, camundongo, e, composição
FI20096339L (fi) Liima-aine, menetelmä sen valmistamiseksi sekä sen käyttö
BRPI0823238A2 (pt) Composição, e, método
BRPI0910378A2 (pt) composições imunogênicas anti-amilóides, métodos e usos
GB0810710D0 (en) Vaccine
ZA201100962B (en) Influenza vaccines
GB0816447D0 (en) Vaccine
GB0816284D0 (en) Vaccine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]